CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
Liver biopsy +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02337660
NCT02337660N/ACompleted
CompareCT.gov

Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia

University Hospital, Gentofte, Copenhagen·interventional·Posted Jan 13, 2015·Updated Nov 16, 2018

In Brief

A clinical study evaluating Liver biopsy and Pancreatic clamp for Non-alcoholic Fatty Liver Disease. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to examine whether non-alcoholic fatty liver disease (NAFLD) is associated with hepatic glucagon resistance and hyperglucagonemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-alcoholic Fatty Liver Disease
CountriesDenmark
CollaboratorsThe Novo Nordisk Foundation Center for Basic Metabolic Research

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 13, 2015
Enrollment StartJan 1, 2015
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 11.5 years ago

Interventions

Liver biopsyprocedure

One ultrasound guided liver biopsy

Pancreatic clampother

I.v. infusions of somatostatin and insulin (basal rate) for will be adminstered for 3 hours. Glucagon will administered for 3 hours in total with infusion rates at a basal and a high physiological rate for 1.5 hours each.